Very Long-term Follow-up (> 5 years) of Renal Function of Neuroendocrine Tumor Patients Treated with Five or More Cycles of Peptide Receptor Radionuclide Therapy (PRRNT)


Introduction: Nephrotoxicity is one of the primary concerns in neuroendocrine tumor (NET) patients (pts.) treated with peptide receptor radionuclide therapy (PRRNT).

Aim(s): Long-term (> 5yrs) analyses of the Tubular Extraction Rate (TER) and Glomerular Filtration Rate (GFR) in NET patients after five cycles of PRRNT.

Materials and methods: These analyses consisted of 32 patients treated with at least five cycles of PRRNT (range 5-8) with Y-90 (n=2, each patient treated with seven cycles) or a combination of Y-90 and Lu-177 (n=30) labeled Somatostatin-Receptor analogues (DOTATAE / DOTATOC) under nephrorprotection. Total cumulative administered radioactivity ranged from 16.5 to 41 GBq.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hoersch D, Zachert C, Hommann M, Baum R,

Keywords: Peptide Receptor Radionuclide Therapy, NET, nephrotoxicity, long-term follow-up,

To read the full abstract, please log into your ENETS Member account.